DEN-181 is under clinical development by Dendright and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect DEN-181’s likelihood of approval (LoA) and phase transition for Rheumatoid Arthritis took place on 26 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their DEN-181 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

DEN-181 overview

DEN-181 (Rheumavax) is under development for the treatment of rheumatoid arthritis. The therapeutic candidate is administered intradermally and subcutaneously. The vaccine candidate is composed of autologous modified dendritic cells (DC) pulsed with a mixture of four citrullinated peptide antigens encompassing cit-vimentin, cit-fibrinogen beta chain, a cit-fibrinogen alpha chain and cit-collagen type II. It is a liposome drug product that delivers an immunomodulatory compound and an autoantigenic peptide relevant to the pathophysiology of emergent RA to cells. The therapeutic candidate is developed based on Curcusome platform technology. It was under development for the treatment of multiple sclerosis, celiac disease and type 1 diabetes.

Quick View DEN-181 LOA Data

Report Segments
  • Innovator
Drug Name
  • DEN-181
Administration Pathway
  • Intradermal
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Immunology
  • Metabolic Disorders
Key Developers
  • Sponsor Company: Dendright
  • Originator: University of Queensland
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.